Off-target analysis

Learn about how Ark Therapeutics ensured their lead molecule had no significant genomics off-targets.

ARK Therapeutics is concentrated to manufacturing of adenoviral vectors used in gene therapy, and to study and manufacturing of gene therapies. Ark Therapeutics has a gene therapy center and production facility is Kuopio, Finland.


Ark Therapeutics was developing a gene therapy for cancer. They had a lead molecule targeting a specific gene and hoped to find out if there were any unwanted off-target effects.


We developed a combined sequence analysis and gene expression pipeline that categorized genes into targets, secondary targets and off-targets.


The categorization of differentially expressed genes showed how the gene regulation cascade was due to silencing of the primary target, and that the therapy had no significant off-target effects.

Do you want to learn more about this case? Please ask for more from our bioinformatician by using the contact form below!